S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:HARP

Harpoon Therapeutics Competitors

$17.65
-1.49 (-7.78 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.67
Now: $17.65
$19.14
50-Day Range
$17.85
MA: $20.29
$24.16
52-Week Range
$10.27
Now: $17.65
$25.24
Volume612,548 shs
Average Volume322,264 shs
Market Capitalization$447.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.87

Competitors

Harpoon Therapeutics (NASDAQ:HARP) Vs. CCCC, TBIO, OCGN, REPL, SGMO, and KRYS

Should you be buying HARP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Harpoon Therapeutics, including C4 Therapeutics (CCCC), Translate Bio (TBIO), Ocugen (OCGN), Replimune Group (REPL), Sangamo Therapeutics (SGMO), and Krystal Biotech (KRYS).

C4 Therapeutics (NASDAQ:CCCC) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Profitability

This table compares C4 Therapeutics and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
C4 TherapeuticsN/AN/AN/A
Harpoon Therapeutics-434.74%-68.32%-29.45%

Analyst Ratings

This is a summary of current ratings and target prices for C4 Therapeutics and Harpoon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
C4 Therapeutics00303.00
Harpoon Therapeutics00703.00

C4 Therapeutics currently has a consensus price target of $39.50, indicating a potential downside of 5.12%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than C4 Therapeutics.

Valuation & Earnings

This table compares C4 Therapeutics and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4 TherapeuticsN/AN/AN/AN/AN/A
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

C4 Therapeutics has higher earnings, but lower revenue than Harpoon Therapeutics.

Institutional & Insider Ownership

79.0% of Harpoon Therapeutics shares are owned by institutional investors. 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Harpoon Therapeutics beats C4 Therapeutics on 5 of the 8 factors compared between the two stocks.

Translate Bio (NASDAQ:TBIO) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Profitability

This table compares Translate Bio and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Translate Bio-70.38%-27.54%-12.82%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Volatility & Risk

Translate Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Translate Bio and Harpoon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Translate Bio00803.00
Harpoon Therapeutics00703.00

Translate Bio currently has a consensus price target of $32.00, indicating a potential upside of 43.95%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Translate Bio.

Valuation & Earnings

This table compares Translate Bio and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Translate Bio$7.80 million211.82$-113,290,000.00($1.84)-12.08
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

Harpoon Therapeutics has lower revenue, but higher earnings than Translate Bio. Translate Bio is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.9% of Translate Bio shares are owned by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are owned by institutional investors. 12.3% of Translate Bio shares are owned by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Translate Bio beats Harpoon Therapeutics on 9 of the 13 factors compared between the two stocks.

Ocugen (NASDAQ:OCGN) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Profitability

This table compares Ocugen and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OcugenN/A-47.72%-30.78%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Volatility & Risk

Ocugen has a beta of 3.56, meaning that its stock price is 256% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Ocugen and Harpoon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ocugen01302.75
Harpoon Therapeutics00703.00

Ocugen currently has a consensus price target of $4.80, indicating a potential downside of 45.08%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Ocugen.

Valuation & Earnings

This table compares Ocugen and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OcugenN/AN/A$-20,240,000.00($1.48)-5.91
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

Ocugen has higher earnings, but lower revenue than Harpoon Therapeutics. Harpoon Therapeutics is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

8.5% of Ocugen shares are owned by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Harpoon Therapeutics beats Ocugen on 7 of the 13 factors compared between the two stocks.

Replimune Group (NASDAQ:REPL) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation & Earnings

This table compares Replimune Group and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A$-52,630,000.00($1.54)-22.93
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

Replimune Group has higher earnings, but lower revenue than Harpoon Therapeutics. Replimune Group is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Replimune Group and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Replimune GroupN/A-30.23%-24.66%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Institutional & Insider Ownership

55.8% of Replimune Group shares are owned by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are owned by institutional investors. 50.9% of Replimune Group shares are owned by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Replimune Group has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Replimune Group and Harpoon Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Replimune Group00903.00
Harpoon Therapeutics00703.00

Replimune Group currently has a consensus price target of $56.00, indicating a potential upside of 58.60%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Replimune Group.

Summary

Replimune Group beats Harpoon Therapeutics on 8 of the 12 factors compared between the two stocks.

Sangamo Therapeutics (NASDAQ:SGMO) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Sangamo Therapeutics and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sangamo Therapeutics$102.43 million15.89$-95,190,000.00($0.85)-13.36
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

Harpoon Therapeutics has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sangamo Therapeutics and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sangamo Therapeutics-51.51%-16.32%-9.85%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Institutional and Insider Ownership

57.7% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Sangamo Therapeutics has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sangamo Therapeutics and Harpoon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sangamo Therapeutics02402.67
Harpoon Therapeutics00703.00

Sangamo Therapeutics presently has a consensus price target of $20.20, indicating a potential upside of 77.82%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Sangamo Therapeutics.

Summary

Harpoon Therapeutics beats Sangamo Therapeutics on 8 of the 14 factors compared between the two stocks.

Krystal Biotech (NASDAQ:KRYS) and Harpoon Therapeutics (NASDAQ:HARP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Valuation and Earnings

This table compares Krystal Biotech and Harpoon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-60.62
Harpoon Therapeutics$5.78 million77.50$-55,570,000.00($2.55)-6.92

Krystal Biotech has higher earnings, but lower revenue than Harpoon Therapeutics. Krystal Biotech is trading at a lower price-to-earnings ratio than Harpoon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Krystal Biotech and Harpoon Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Krystal BiotechN/A-10.72%-10.40%
Harpoon Therapeutics-434.74%-68.32%-29.45%

Institutional and Insider Ownership

73.1% of Krystal Biotech shares are owned by institutional investors. Comparatively, 79.0% of Harpoon Therapeutics shares are owned by institutional investors. 27.4% of Krystal Biotech shares are owned by company insiders. Comparatively, 34.9% of Harpoon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Krystal Biotech has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Harpoon Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Krystal Biotech and Harpoon Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Krystal Biotech00603.00
Harpoon Therapeutics00703.00

Krystal Biotech presently has a consensus price target of $101.00, indicating a potential upside of 38.85%. Harpoon Therapeutics has a consensus price target of $31.5714, indicating a potential upside of 78.87%. Given Harpoon Therapeutics' higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Krystal Biotech.


Harpoon Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$41.63-6.1%$1.79 billionN/A0.00Upcoming Earnings
News Coverage
Gap Up
Translate Bio logo
TBIO
Translate Bio
1.4$22.23-4.2%$1.65 billion$7.80 million-20.78Upcoming Earnings
Analyst Revision
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.74-2.6%$1.64 billionN/A-5.91Analyst Report
Unusual Options Activity
Analyst Revision
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$35.31-8.5%$1.64 billionN/A-19.95High Trading Volume
News Coverage
Gap Up
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.36-1.1%$1.63 billion$102.43 million-18.93Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$72.74-1.5%$1.61 billionN/A-49.15Earnings Announcement
Analyst Upgrade
Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.93-1.8%$1.49 billion$35.23 million-16.10Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.87-1.3%$1.39 billion$100.56 million0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$17.07-4.8%$1.36 billion$21.22 million-7.65Analyst Upgrade
News Coverage
Gap Up
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$16.07-1.1%$1.34 billionN/A-3.48Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.51-3.2%$1.32 billionN/A-10.47Increase in Short Interest
PCVX
Vaxcyte
1.8$23.76-0.6%$1.21 billionN/A0.00Upcoming Earnings
Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.83-3.7%$1.15 billion$356.07 million7.76Analyst Report
Gap Up
Cortexyme logo
CRTX
Cortexyme
1.3$37.99-4.3%$1.12 billionN/A-15.83Earnings Announcement
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$29.36-20.3%$1.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.12-1.4%$1.09 billion$250,000.00-8.76Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$9.17-0.1%$1.08 billion$32.16 million-10.42Earnings Announcement
Analyst Upgrade
Analyst Revision
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.3$12.56-17.2%$1.02 billionN/A-5.87News Coverage
Gap Up
Inhibrx logo
INBX
Inhibrx
1.7$26.39-0.6%$995.22 millionN/A0.00Upcoming Earnings
Gap Down
Passage Bio logo
PASG
Passage Bio
1.9$19.83-2.0%$910.53 millionN/A0.00Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Gap Up
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.10-5.5%$906.51 millionN/A-4.15News Coverage
Gap Up
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.75-2.7%$879.69 million$69.89 million-4.47Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$22.41-3.9%$854.22 millionN/A0.00Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.80-3.0%$828.87 millionN/A-10.25
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$21.11-3.9%$814.93 million$42.74 million-234.56Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.13-2.3%$794.02 million$1.12 million-5.18Analyst Upgrade
Gap Up
Cellectis logo
CLLS
Cellectis
1.3$18.19-6.2%$772.82 million$22.99 million-9.68Earnings Announcement
News Coverage
Gap Down
Vaxart logo
VXRT
Vaxart
1.3$6.02-1.7%$708.96 million$9.86 million-10.20Analyst Report
Analyst Revision
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.76-1.5%$657.51 million$2.51 million-4.10Earnings Announcement
Analyst Report
Increase in Short Interest
Analyst Revision
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$31.54-2.9%$640.89 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.18-0.6%$623.06 millionN/A0.00Upcoming Earnings
Decrease in Short Interest
News Coverage
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.20-1.3%$608.48 million$150.05 million-2.94
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.50-4.2%$603.52 million$22.24 million-5.72Upcoming Earnings
Analyst Report
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.21-3.6%$572.36 million$14.75 million-2.24Upcoming Earnings
Gap Up
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$12.60-9.1%$571.96 million$147.87 million-4.19Analyst Upgrade
News Coverage
Gap Up
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$9.40-6.1%$568.22 millionN/A-4.56Upcoming Earnings
News Coverage
Gap Up
Compugen logo
CGEN
Compugen
1.4$8.30-1.6%$567.54 million$17.80 million-22.42Analyst Downgrade
High Trading Volume
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.56-4.5%$559.28 million$13.29 million-10.33Upcoming Earnings
News Coverage
Gap Up
Curis logo
CRIS
Curis
1.3$9.47-3.6%$557.00 million$10 million-11.55Increase in Short Interest
Gap Up
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.3$21.00-2.7%$544.11 millionN/A-6.05
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$8.63-7.5%$533.51 millionN/A-1.26Upcoming Earnings
High Trading Volume
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.57-0.1%$512.46 million$4.36 million-4.74Upcoming Earnings
Increase in Short Interest
Gap Down
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.25-1.6%$469.42 millionN/A0.00Upcoming Earnings
AVROBIO logo
AVRO
AVROBIO
1.7$11.32-6.9%$412.63 millionN/A-3.43Gap Up
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
Opthea logo
OPT
Opthea
1.5$9.11-2.6%$384.55 millionN/A0.00Decrease in Short Interest
Gap Down
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.72-5.6%$360.15 million$250,000.00-3.47Analyst Revision
Gap Up
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.68-1.3%$354.47 millionN/A0.00Gap Up
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.31-0.2%$340.41 million$96.12 million-12.68Upcoming Earnings
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.55-2.2%$336.45 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Gap Up
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.